Advertisement

COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer

  • Author Footnotes
    † These authors share first coauthorship.
    Meredith Mihalopoulos
    Footnotes
    † These authors share first coauthorship.
    Affiliations
    Department of Urology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Search for articles by this author
  • Author Footnotes
    † These authors share first coauthorship.
    Navneet Dogra
    Footnotes
    † These authors share first coauthorship.
    Affiliations
    Department of Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Search for articles by this author
  • Nihal Mohamed
    Affiliations
    Department of Urology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Search for articles by this author
  • Ketan Badani
    Correspondence
    Corresponding authors. Department of Urology, Icahn School of Medicine at Mount Sinai, 6th Floor, 1425, Madison Avenue, New York, NY 10029, USA. Tel.: +1 212 639 9371; Fax: +1 212 876-3246.
    Affiliations
    Department of Urology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Search for articles by this author
  • Natasha Kyprianou
    Correspondence
    Corresponding authors. Department of Urology, Icahn School of Medicine at Mount Sinai, 6th Floor, 1425, Madison Avenue, New York, NY 10029, USA. Tel.: +1 212 639 9371; Fax: +1 212 876-3246.
    Affiliations
    Department of Urology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Search for articles by this author
  • Author Footnotes
    † These authors share first coauthorship.

      Abstract

      Context

      The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic that erupted in December 2019 has affected more than a million people from over 200 countries, claiming over 70 000 lives (by April 7, 2020). As the viral infection is driven by increased angiotensin-converting enzyme-2 (ACE2) expression, with the kidney exhibiting the highest expression, it is crucial to gain insights into the mechanisms underlying renal cell carcinoma (RCC) and coronavirus disease 2019 (COVID-19).

      Objective

      This study considers up-to-date information on the biological determinants shared by COVID-19 and renal disease, and aims to provide evidence-based recommendations for the clinical management of RCC patients with COVID-19.

      Evidence acquisition

      A literature search was performed using all sources (MEDLINE, EMBASE, ScienceDirect, Cochrane Libraries, and Web of Science). As of March 31, 2020, the Center for Disease Control reported that of the adults hospitalized for COVID-19 with underlying conditions in the USA, 74.8% had chronic renal disease.

      Evidence synthesis

      Evidence is discussed from epidemiological studies on SARS-CoV-2 pandemic and molecular studies on the role of kidney in facilitating routes for SARS-CoV-2 entry, leading to increased virulence of SARS-CoV-2 and clinical manifestation of symptoms in RCC.

      Conclusions

      This analysis will advance our understanding of (1) the molecular signatures shared by RCC and COVID-19 and (2) the clinical implications of overlapping signaling pathways in the therapeutic management of RCC and COVID-19 patients.

      Patient summary

      Amid the coronavirus disease 2019 (COVID-19) pandemic, patients diagnosed with renal cell carcinoma and infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may receive complimentary treatment modalities to enhance therapeutic response.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Urology Focus
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. In press. https://doi.org/10.1002/jmv.25722.

        • Chen Y.
        • Liu Q.
        • Guo D.
        Emerging coronaviruses: genome structure, replication, and pathogenesis.
        J Med Virol. 2020; 92: 418-423
        • World Health Organization
        Coronavirus disease 2019 (COVID-19) situation report—78.
        2020
        • Perico L.
        • Benigni A.
        • Remuzzi G.
        Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade.
        Nephron. 2020; 24126: 1-9
        • Guan W.
        • Ni Z.
        • Hu Y.
        • et al.
        Clinical characteristics of coronavirus disease 2019 in China.
        N Engl J Med. 2020; 382: 1708-1720
        • Chen N.
        • Zhou M.
        • Dong X.
        • et al.
        Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
        Lancet. 2020; 395: 507-513
        • Patel A.B.
        • Verma A.
        COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?.
        JAMA. 2020; 323: 1769-1770
        • Cheng Y.
        • Luo R.
        • Wang K.
        • et al.
        Kidney disease is associated with in-hospital death of patients with COVID-19.
        Kidney Int. 2020; 97: 829-838
      2. Diao B, Feng Z, Wang C, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv. In press. https://doi.org/10.1101/2020.03.04.20031120.

      3. Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is there an association between COVID-19 mortality and the renin-angiotensin system—a call for epidemiologic investigations. Clin Infect Dis. In press. https://doi.org/10.1093/cid/ciaa329.

        • Wrapp D.
        • Wang N.
        • Corbett K.S.
        • et al.
        Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
        Science. 2020; 367: 1260-1263
      4. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. In press. https://doi.org/10.1101/2020.01.31.929042.

        • Hoffmann M.
        • Kleine-Weber H.
        • Schroeder S.
        • et al.
        SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.
        Cell. 2020; 181: 1-10
        • Patel V.B.
        • Zhong J.-C.
        • Grant M.B.
        • Oudit G.Y.
        Role of the ACE2/angiotensin 1–7 axis of the renin-angiotensin system in heart failure.
        Circ Res. 2016; 118: 1313-1326
        • Anguiano L.
        • Riera M.
        • Pascual J.
        • Soler M.J.
        Circulating ACE2 in cardiovascular and kidney diseases.
        Curr Med Chem. 2017; 24: 3231-3241
        • de Farias Lelis D.
        • de Freitas D.F.
        • Machado A.S.
        • Crespo T.S.
        • Santos S.H.S.
        Angiotensin-(1-7), adipokines and inflammation.
        Metabolism. 2019; 95: 36-45
        • Gonzalez L.
        • Novoa U.
        • Moya J.
        • et al.
        Angiotensin-(1-9) reduces cardiovascular and renal inflammation in experimental renin-independent hypertension.
        Biochem Pharmacol. 2018; 156: 357-370
        • Donoghue M.
        • Hsieh F.
        • Baronas E.
        • et al.
        A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.
        Circ Res. 2000; 87: e1-9
        • Li X.C.
        • Zhang J.
        • Zhuo J.L.
        The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.
        Pharmacol Res. 2017; 125: 21-38
        • Ferrario C.M.
        • Jessup J.
        • Chappell M.C.
        • et al.
        Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.
        Circulation. 2005; 111: 2605-2610
        • Qiao W.
        • Wang C.
        • Chen B.
        • et al.
        Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats.
        Cardiology. 2015; 131: 97-106
        • Zheng Y.Y.
        • Ma Y.T.
        • Zhang J.Y.
        • Xie X.
        COVID-19 and the cardiovascular system.
        Nat Rev Cardiol. 2020; 17: 259-260
      5. Xu D, Zhang H, Zhou W, Wang LH, Cui XG. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak : a study based on single-cell transcriptome analysis. Intensive Care Med. In press. https://doi.org/10.1007/s00134-020-06026-1.

      6. https://doi.org/10.1101/2020.02.08.20021212Li Z, Wu M, Guo J, et al. Caution on kidney dysfunctions of 2019-nCoV patients. MedRxiv. In press. .

        • Wang D.
        • Hu B.
        • Hu C.
        • et al.
        Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.
        JAMA. 2020; 323: 1061-1069
        • CDC COVID-19 Response Team
        Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020.
        MMWR Morb Mortal Wkly Rep. 2020; 69: 382-386
        • Ueda M.
        • Martins R.
        • Hendrie P.C.
        • et al.
        Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal.
        J Natl Compr Canc Netw. 2020; 18: 1-4
        • Board on Health Care Services Institute of Medicine
        The role of telehealth in an evolving health care environment, workshop summary.
        National Academies Press, Washington, DC2012
        • Wang Y.
        • Zhou S.
        • Yang F.
        • et al.
        Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis.
        JAMA Oncol. 2019; 5: 1008-1019
        • Singhal T.
        A review of coronavirus disease-2019 (COVID-19).
        Indian J Pediatr. 2020; 87: 281-286
        • Abbott B.
        U.S. coronavirus patients with other conditions hospitalized at higher rates.
        The Wall Street Journal. 2020;
        • Bhatraju P.K.
        • Ghassemieh B.J.
        • Nichols M.
        • et al.
        COVID-19 in critically ill patients in the Seattle region—case series.
        N Engl J Med. 2020; 382: 2012-2022
      7. Wang L, Li X, Chen H, et al. SARS-CoV-2 infection does not significantly cause acute renal injury: an analysis of 116 hospitalized patients with COVID-19 in a single hospital, Wuhan, China. SSRN Electron J. In press. https://doi.org/10.2139/ssrn.3541116.

        • Naicker S.
        • Yang C.W.
        • Naicker S.
        • Yang C.W.
        • Hwang S.J.
        • Liu B.C.
        • Chen J.H.
        • Jha V.
        The novel coronavirus 2019 epidemic and kidneys.
        Kidney Int. 2020; 97: 824-828
        • Extance A.
        Covid-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease?.
        BMJ. 2020; 368: m1174
        • Kliger A.S.
        • Silberzweig J.
        Mitigating Risk of COVID-19 in Dialysis Facilities.
        Clin J Am Soc Nephrol. 2020; 15: 707-709
        • Basile C.
        • Combe C.
        • Pizzarelli F.
        • et al.
        Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres.
        Nephrol Dial Transplant. 2020; 35: 737-741
        • Chu K.H.
        • Tsang W.K.
        • Tang C.S.
        • et al.
        Acute renal impairment in coronavirus-associated severe acute respiratory syndrome.
        Kidney Int. 2006; 67: 698-705
        • Betjes M.G.H.
        Immune cell dysfunction and inflammation in end-stage renal disease.
        Nat Rev Nephrol. 2013; 9: 255-265
        • Jung J.Y.
        • Park B.H.
        • Hong S.B.
        • et al.
        Acute kidney injury in critically ill patients with pandemic influenza A pneumonia 2009 in Korea: a multicenter study.
        J Crit Care. 2011; 26: 577-585
      8. Cao M, Zhang D, Wang Y, et al. Clinical features of patients infected with the 2019 novel coronavirus (COVID-19) in Shanghai, China. medRxiv. In press. https://doi.org/10.1101/2020.03.04.20030395.

        • Huang C.
        • Wang Y.
        • Li X.
        • et al.
        Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
        Lancet. 2020; 395: 497-506
        • Jefferson J.A.
        • Nelson P.J.
        • Najafian B.
        • Shankland S.J.
        Podocyte disorders: core curriculum 2011.
        Am J Kidney Dis. 2011; 58: 666-677
        • Huang K.J.
        • Su I.J.
        • Theron M.
        • et al.
        An interferon-γ-related cytokine storm in SARS patients.
        J Med Virol. 2005; 75: 185-194
        • Capitanio U.
        • Bensalah K.
        • Bex A.
        • et al.
        Epidemiology of renal cell carcinoma.
        Eur Urol. 2019; 75: 74-84
        • Liang W.
        • Guan W.
        • Chen R.
        • et al.
        Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.
        Lancet Oncol. 2020; 21: 335-337
        • Barry R.E.
        • Krek W.
        The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis.
        Trends Mol Med. 2004; 10: 466-472
        • Négrier S.
        • Raymond E.
        Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.
        Invest New Drugs. 2012; 30: 1791-1801
        • Aoun F.
        • Rassy E.E.
        • Assi T.
        • Kattan J.
        PDL-1/PD1 inhibitors: antibody or antinobody?.
        Future Oncol. 2017; 13: 1669-1671
        • Labriola M.K.
        • Zhu J.
        • Gupta R.
        • et al.
        Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
        J Immunother Cancer. 2020; 8e000319
        • Escudier B.
        • Porta C.
        • Schmidinger M.
        • et al.
        Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2016; 27: v58-68
        • Albiges L.
        • Powles T.
        • Staehler M.
        • et al.
        Updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma.
        Eur Urol. 2019; 76: 151-156
        • Rassy E.
        • Flippot R.
        • Albiges L.
        Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma.
        Ther Adv Med Oncol. 2018; 12: 1-13
        • Bersanelli M.
        Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.
        Immunotherapy. 2020; 12: 269-273
        • Sobczuk P.
        • Szczylik C.
        • Porta C.
        • Czarnecka A.M.
        Renin angiotensin system deregulation as renal cancer risk factor (Review).
        Oncol Lett. 2017; 14: 5059-5068
        • Araújo W.F.
        • Naves M.A.
        • Ravanini J.N.
        • Schor N.
        • Teixeira V.P.C.
        Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice.
        Urol Oncol Semin Orig Investig. 2015; 33: 389.e1-389.e7
        • Dolley-Hitze T.
        • Jouan F.
        • Martin B.
        • et al.
        Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma.
        Br J Cancer. 2010; 103: 1698-1705
        • Larrinaga G.
        • Pérez I.
        • Sanz B.
        • et al.
        Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors.
        Regul Pept. 2010; 165: 218-223
        • Ni L.
        • Feng Y.
        • Wan H.
        • et al.
        Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways.
        Oncol Rep. 2012; 27: 783-790
        • Soto-Pantoja D.R.
        • Menon J.
        • Gallagher P.E.
        • Tallant E.A.
        Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor.
        Mol Cancer Ther. 2009; 8: 1676-1683
        • Gallagher P.E.
        • Tallant E.A.
        Inhibition of human lung cancer cell growth by angiotensin-(1-7).
        Carcinogenesis. 2004; 25: 2045-2052
        • Enevoldsen F.C.
        • Sahana J.
        • Wehland M.
        • Grimm D.
        • Infanger M.
        • Krüger M.
        Endothelin receptor antagonists: status quo and future perspectives for targeted therapy.
        J Clin Med. 2020; 9: 824
        • Houde M.
        • Desbiens L.
        • D’Orléans-Juste P.
        Endothelin-1: biosynthesis, signaling and vasoreactivity.
        Adv Pharmacol. 2016; 77: 143-175
        • Diaz L.A.
        • Bardelli A.
        Liquid biopsies: genotyping circulating tumor DNA.
        J Clin Oncol. 2014; 32: 579-586
        • Smith J.T.
        • Wunsch B.H.
        • Dogra N.
        • et al.
        Integrated nanoscale deterministic lateral displacement arrays for separation of extracellular vesicles from clinically-relevant volumes of biological samples.
        Lab Chip. 2018; 18: 3913-3925
        • Stott S.L.
        • Hsu C.H.
        • Tsukrov D.I.
        • et al.
        Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.
        Proc Natl Acad Sci U S A. 2010; 107: 18392-18397
        • Murillo O.
        • Thistlethwaite W.
        • Rozowsky J.
        • et al.
        ExRNA Atlas analysis reveals distinct extracellular RNA cargo types and their carriers present across human biofluids.
        Cell. 2019; 177: 463-477
        • Navneet D.
        • Xuelian L.
        • Kohli P.
        Investigating ligand−receptor interactions at bilayer surface using electronic absorption spectroscopy and fluorescence resonance energy transfer.
        Langmuir. 2012; 28: 12989-12998
        • Redova M.
        • Poprach A.
        • Nekvindova J.
        • et al.
        Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma.
        J Transl Med. 2012; 10: 55https://doi.org/10.1186/1479-5876-10-55
        • Karachaliou N.
        • Mayo-de-las-Casas C.
        • Molina-Vila M.A.
        • Rosell R.
        Real-time liquid biopsies become a reality in cancer treatment.
        Ann Transl Med. 2015; 3: 2-4
        • Raimondo F.
        • Morosi L.
        • Corbetta S.
        • et al.
        Differential protein profiling of renal cell carcinoma urinary exosomes.
        Mol Biosyst. 2013; 9: 1220-1233
        • Wang W.
        • Xu Y.
        • Gao R.
        • et al.
        Detection of SARS-CoV-2 in different types of clinical specimens.
        JAMA. 2020; 323: 1843-1844
        • Arabi Y.M.
        • Arifi A.A.
        • Balky H.H.
        • et al.
        Clinical course and outcomes of critically Ill patients with Middle East respiratory syndrome coronavirus infection.
        Ann Intern Med. 2014; 160: 389-397
        • Russell C.D.
        • Millar J.E.
        • Baillie J.K.
        Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.
        Lancet. 2020; 395: 473-475
        • Kruse R.L.
        Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.
        F1000Research. 2020; 9: 72
        • Park B.K.
        • Maharjan S.
        • Lee S.I.
        • et al.
        Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex.
        BMB Rep. 2019; 52: 397-402
        • Chu C.M.
        • Cheng V.C.C.
        • Hung I.F.N.
        • et al.
        Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings.
        Thorax. 2004; 59: 252-256
        • Holshue M.L.
        • DeBolt C.
        • Lindquist S.
        • et al.
        First case of 2019 novel coronavirus in the United States.
        N Engl J Med. 2020; 382: 929-936
        • Zumla A.
        • Chan J.F.W.
        • Azhar E.I.
        • Hui D.S.C.
        • Yuen K.Y.
        Coronaviruses—drug discovery and therapeutic options.
        Nat Rev Drug Discov. 2016; 15: 327-347
        • Yang N.
        • Shen H.-M.
        Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19.
        Int J Biol Sci. 2020; 16: 1724-1731
        • Wong S.K.
        • Li W.
        • Moore M.J.
        • Choe H.
        • Farzan M.
        A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.
        J Biol Chem. 2004; 279: 3197-3201